PTEN and cancer: Cancer cells with increased activation of the PI3K pathway often have either overexpression/mutation of upstream receptor tyrosine kinases (e.g., human epidermal growth factor receptor), or loss-of-function of the negative PI3K regulator/tumor suppressor, PTEN.